Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

4 treatments under study, led by Exendin939 At Low Dose

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

1Total
Phase 1 (1)

Trial Status

Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (1)

Showing 1 of 1 trials
NCT01218633Phase 1CompletedPrimary

Dose-response Study of Exendin-9,39 on Glucose Metabolism

Showing all 1 trials

Research Network

Common Treatments

  • Exendin939 At Low Dose1
  • Saline Infusion1
  • Glp1936 Infusion1
  • Exendin939 At High Dose1

Active Sponsors

  • Adrian Vella1

Top Investigators

Activity Timeline